Screener
Amneal Pharmaceuticals, Inc. AMRX Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 9, 2023.
- Filed
- May 9, 2023
- Fiscal quarter
- Q1 FY2023
- Calendar quarter
- Q1 2023
- Accession
- 0001723128-23-000020
| Line item | March 31, 2023 | December 31, 2022 |
|---|---|---|
| Operating lease liabilities - related party | 15,163 | 15,914 |
| Financing lease liabilities | 60,241 | 60,769 |
| Related party payables - long term | 11,207 | 9,649 |
| Other long-term liabilities | 41,456 | 87,468 |
| Total long-term liabilities | 2,760,701 | 2,837,613 |
| Commitments and contingencies (Notes 5 and 19) | ||
| Redeemable non-controlling interests | 27,527 | 24,949 |
| Stockholders' Equity |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s other non-current liabilities?
- Amneal Pharmaceuticals, Inc. (AMRX) reported other non-current liabilities of $41.46M in Q1 2023.
- How has Amneal Pharmaceuticals, Inc.'s other non-current liabilities changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s other non-current liabilities increased by 26.1% year-over-year, from $32.87M to $41.46M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s other non-current liabilities?
- Over 2 years (2020 to 2022), Amneal Pharmaceuticals, Inc.'s other non-current liabilities has grown at a 2.4% compound annual growth rate (CAGR), from $83.37M to $87.47M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Amneal Pharmaceuticals, Inc.'s other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude